MedTrace Logo

Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer

NCT01278212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2024-02-22

Study results available
· View outcomes & findings →

Summary

The goal of this study is to explore the safety, effectiveness, quality of life, and cost effectiveness of accelerated hypofractionated radiotherapy (AHF-RT) as treatment after lumpectomy in patients with early stage breast cancer.

Conditions

Interventions

RADIATION

accelerated hypofractionated radiotherapy (AHF-RT)

30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy

Sponsors & Collaborators

  • James Graham Brown Cancer Center

    collaborator OTHER

  • University of Louisville

    lead OTHER

Principal Investigators

  • Harriet Eldredge-Hindy, MD · James Graham Brown Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2021-01-27
Completion
2021-01-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01278212 on ClinicalTrials.gov